Application of huperzine A in preparation of medicine for preventing and/or treating pulmonary fibrosis

• Main Authors: DONG WENXIN, DENG JING, XU CHUNHUA, YAN RENJIE, CHEN JIAYU, CAI JINNA, LI BAOYU, YUAN YUNYUN, HOU HAIFANG, CHEN CHUNLIN, ZHENG KAILU, YAO YUANSHAN
• Format: Patent
• Language: Chinese; English
• Published: 22.09.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides application of huperzine A in preparation of a medicine for preventing and/or treating pulmonary fibrosis. A bleomycin-induced in-vitro pulmonary fibrosis disease model is adopted, and it is proved that huperzine A can serve as an aromatic hydrocarbon receptor agonist to increase expression of an aromatic hydrocarbon receptor in cells; a mouse pulmonary fibrosis disease model induced by bleomycin is adopted, and it is proved that huperzine A has anti-pulmonary fibrosis pharmacological activity. By researching the in-vivo and in-vitro biological activity of huperzine A for resisting pulmonary fibrosis diseases, a new thought and scheme are provided for research, development and production of anti-fibrosis drugs. 本发明提供了石杉碱甲在制备预防和/或治疗抗肺纤维化药物中的应用。本发明采用博莱霉素诱导的体外肺纤维化疾病模型，证明了石杉碱甲可作为芳烃受体激动剂升高芳烃受体在细胞内的表达；采用博莱霉素诱导的小鼠肺纤维化疾病模型，证明了石杉碱甲具有抗肺纤维化的药理活性。本发明通过研究石杉碱甲抗肺纤维化疾病在体内外的生物活性，为抗纤维化药物的研发和生产提供了新的思路和方案。